Patents by Inventor Susann Cattepoel

Susann Cattepoel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies against the beta-amyloid peptide
    Patent number: 9273126
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 1, 2016
    Assignees: Delenex Therapeutics AG, University of Zurich
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
  • HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE
    Publication number: 20130345292
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Application
    Filed: November 2, 2012
    Publication date: December 26, 2013
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
  • Humanized antibodies against the ?-amyloid peptide
    Patent number: 8323647
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: December 4, 2012
    Assignees: Delenex Therapeutics AG, University of Zurich
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
  • HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE
    Publication number: 20110020220
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Application
    Filed: September 15, 2008
    Publication date: January 27, 2011
    Applicants: Delenex Therapeutics AG, University of Zurich Prorektorat Forschung
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch